Despite these limitations, our study illuminates the significance of the E380Q mutation, the high prevalence of the ESR1 mutations in metastatic ER + breast cancer, the fidelity of cfDNA testing for the ESR1 mutations and the unique evolution of the ESR1 mutations under the selective pressure of AI treatment in the adjuvant and metastatic settings. Here, ESR1 is linked to breast carcinoma.